[go: up one dir, main page]

WO2007031091A3 - Rna antagonist compounds for the modulation of p21 ras expression - Google Patents

Rna antagonist compounds for the modulation of p21 ras expression Download PDF

Info

Publication number
WO2007031091A3
WO2007031091A3 PCT/DK2006/000512 DK2006000512W WO2007031091A3 WO 2007031091 A3 WO2007031091 A3 WO 2007031091A3 DK 2006000512 W DK2006000512 W DK 2006000512W WO 2007031091 A3 WO2007031091 A3 WO 2007031091A3
Authority
WO
WIPO (PCT)
Prior art keywords
ras
expression
oligonucleotides
modulation
lung
Prior art date
Application number
PCT/DK2006/000512
Other languages
French (fr)
Other versions
WO2007031091A2 (en
Inventor
Kees Fluiter
Frank Baas
Bo Hansen
Majken Westergaard
Original Assignee
Santaris Pharma As
Kees Fluiter
Frank Baas
Bo Hansen
Majken Westergaard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As, Kees Fluiter, Frank Baas, Bo Hansen, Majken Westergaard filed Critical Santaris Pharma As
Publication of WO2007031091A2 publication Critical patent/WO2007031091A2/en
Publication of WO2007031091A3 publication Critical patent/WO2007031091A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Oligonucleotides directed against the p21 Ras genes are provided for modulating the expression of p21 Ras. The compositions comprise oligonucleotides, particularly antisense oligonucleotides, targeted to nucleic acids encoding Ha-ras, Ki-ras and N-ras. Methods of using these compounds for modulation of p21 Ras expression and for the treatment of diseases associated with either overexpression of p21 Ras, expression of mutated p21 Ras or both are provided. Examples of diseases are cancer such as lung, breast, colon, prostate, pancreas, lung, liver, thyroid, kidney, brain, testes, stomach, intestine, bowel, spinal cord, sinuses, bladder, urinary tract or ovaries cancers. The oligonucleotides may be composed of deoxyribonucleotides or a nucleic acid analogue such as for example locked nucleic acid or a combination thereof.
PCT/DK2006/000512 2005-09-15 2006-09-15 Rna antagonist compounds for the modulation of p21 ras expression WO2007031091A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71809005P 2005-09-15 2005-09-15
US60/718,090 2005-09-15
US79275906P 2006-04-18 2006-04-18
US60/792,759 2006-04-18
DKPA200600537 2006-04-18
DKPA200600537 2006-04-18

Publications (2)

Publication Number Publication Date
WO2007031091A2 WO2007031091A2 (en) 2007-03-22
WO2007031091A3 true WO2007031091A3 (en) 2007-08-16

Family

ID=37603005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2006/000512 WO2007031091A2 (en) 2005-09-15 2006-09-15 Rna antagonist compounds for the modulation of p21 ras expression

Country Status (1)

Country Link
WO (1) WO2007031091A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852627B2 (en) 2015-11-12 2023-12-26 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression

Families Citing this family (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468895B1 (en) 2006-01-05 2014-09-24 The Ohio State University Research Foundation MicroRNA-based methods and compositions for the diagnosis and treatment of solid cancers
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
EA201100810A1 (en) 2006-04-03 2012-06-29 Сантарис Фарма А/С PHARMACEUTICAL COMPOSITION
WO2007112754A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical compositions comprising anti-mirna antisense oligonucleotides
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
TW200848077A (en) 2007-05-01 2008-12-16 Santaris Pharma As Compounds for the modulation of beta-cantenin expression
JP2010526797A (en) 2007-05-11 2010-08-05 エンゾン ファーマシューティカルズ，インコーポレーテッド RNA antagonist compounds for modulation of HER3
DK2623599T3 (en) 2007-10-04 2019-04-08 Roche Innovation Ct Copenhagen As Micromirers
ES2456990T3 (en) 2007-11-26 2014-04-24 Santaris Pharma A/S LNA-based antagonists targeting the androgen receptor
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
KR20100105648A (en) 2007-12-03 2010-09-29 엔즌 파마슈티칼스, 인코포레이티드 Rna antagonist compounds for the modulation of pik3ca expression
WO2009109665A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2009125607A1 (en) * 2008-04-11 2009-10-15 Sapporo Medical University Apoptosis inducer
ES2541442T3 (en) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S MicroRNA-mediated modulation of colony stimulating factors
KR20110086844A (en) * 2008-11-07 2011-08-01 엔즌 파마슈티칼스, 인코포레이티드 ERW-3 (HSE3)-Selective combination therapy
US9132147B2 (en) 2008-12-31 2015-09-15 Roche Innovation Center Copenhagen Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
AU2010232410B2 (en) 2009-04-03 2016-11-17 Novo Nordisk A/S Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
EP2756845B1 (en) * 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
JP5773535B2 (en) 2009-04-24 2015-09-02 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Pharmaceutical composition for the treatment of HCV patients unresponsive to interferon
NZ596608A (en) 2009-06-12 2014-01-31 Santaris Pharma As New potent anti apob antisense compounds
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011048125A1 (en) 2009-10-20 2011-04-28 Santaris Pharma A/S Oral delivery of therapeutically effective lna oligonucleotides
WO2011054811A1 (en) 2009-11-03 2011-05-12 Santaris Pharma A/S Rna antagonists targeting hsp27 combination therapy
HUE042177T2 (en) 2009-12-01 2019-06-28 Translate Bio Inc Steroid derivative for the delivery of mrna in human genetic diseases
EP3587579B1 (en) 2010-07-06 2021-03-03 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
WO2012007477A1 (en) 2010-07-12 2012-01-19 Santaris Pharma A/S Anti hcv oligomers
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
WO2012066093A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of pdz-binding kinase (pbk) expression
WO2012066092A1 (en) 2010-11-19 2012-05-24 Santaris Pharma A/S Compounds for the modulation of aurora kinase a expression
WO2012110457A2 (en) 2011-02-14 2012-08-23 Santaris Pharma A/S Compounds for the modulation of osteopontin expression
WO2012143427A1 (en) 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
AU2012267578B2 (en) 2011-06-08 2017-04-20 Translate Bio, Inc. Cleavable lipids
RU2013154295A (en) 2011-06-08 2015-07-20 Шир Хьюман Дженетик Терапис, Инк. COMPOSITIONS OF LIPID NANOPARTICLES AND METHODS FOR DELIVERY OF mRNA
KR20140051271A (en) 2011-06-23 2014-04-30 스텔라 에이피에스 Hcv combination therapy
KR20140058536A (en) 2011-06-30 2014-05-14 스텔라 에이피에스 Hcv combination therapy
JP2014520772A (en) 2011-06-30 2014-08-25 ステラ・アンパルトセルスカブ HCV combination therapy
AU2012334214A1 (en) 2011-11-07 2014-05-22 Roche Innovation Center Copenhagen A/S Prognostic method for checking efficacy of micro RNA-122 inhibitors in HCV+ patients
WO2013068348A1 (en) 2011-11-07 2013-05-16 Santaris Pharma A/S Lna oligomers for improvement in hepatic function
EP2776563A1 (en) 2011-11-11 2014-09-17 Santaris Pharma A/S Compounds for the modulation of smn2 splicing
KR20140109430A (en) 2012-01-04 2014-09-15 쿠아크 파마수티칼스 인코퍼레이티드 Double-stranded rna compounds to casp2 and uses thereof
CN105936932A (en) 2012-01-20 2016-09-14 俄亥俄州立大学 Breast cancer biomarker signatures for invasiveness and prognosis
US20130236453A1 (en) * 2012-03-12 2013-09-12 The Ohio State University Methods and Compositions for Modulating Acute Graft-versus-Host Disease using miR-155 Specific Inhibitors
HK1206644A1 (en) 2012-03-29 2016-01-15 Shire Human Genetic Therapies, Inc. Lipid-derived neutral nanoparticles
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
AP2014008100A0 (en) 2012-05-16 2014-12-31 Gen Hospital Corp Compositions and methods for modulating hemoglobingene family expression
EA201492120A1 (en) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING ATP2A2 EXPRESSION
CA2873779A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
SG11201407486PA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating utrn expression
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
AU2013346767B2 (en) 2012-11-15 2019-04-11 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
EP2922955B1 (en) 2012-11-26 2019-03-06 Roche Innovation Center Copenhagen A/S Compositions and methods for modulation of fgfr3 expression
MX2015009056A (en) 2013-01-30 2015-10-05 Hoffmann La Roche Lna oligonucleotide carbohydrate conjugates.
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
DK2970955T3 (en) 2013-03-14 2019-02-11 Translate Bio Inc METHODS FOR CLEANING MESSENGER RNA
KR102248744B1 (en) 2013-03-14 2021-05-06 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna compositions and related methods and uses
HUE071526T2 (en) 2013-03-15 2025-09-28 Translate Bio Inc Synergistic enhancement of the delivery of nucleic acids via blended formulations
KR20160013110A (en) 2013-05-24 2016-02-03 로슈 이노베이션 센터 코펜하겐 에이/에스 Oligonucleotide modulators of b-cell cll/lymphoma 11a(bcl11a) and uses thereof
HRP20200163T1 (en) 2013-06-27 2020-08-07 Roche Innovation Center Copenhagen A/S ANTISENSE OLIGOMERS AND CONJUGATES THAT TARGETLY ACT ON PCSK9
EP3501605B1 (en) 2013-10-22 2023-06-28 Translate Bio, Inc. Mrna therapy for argininosuccinate synthetase deficiency
CA2928186A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Mrna therapy for phenylketonuria
KR101988552B1 (en) 2013-10-22 2019-09-25 샤이어 휴먼 지네틱 테라피즈 인크. Lipid formulations for delivery of messenger rna
US10266828B2 (en) 2013-12-16 2019-04-23 Syddansk Universitet RAS exon 2 skipping for cancer treatment
MX373952B (en) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Methods for purification of messenger rna
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
CN106659731A (en) 2014-05-30 2017-05-10 夏尔人类遗传性治疗公司 Topical compositions and methods for treating wounds
KR102511554B1 (en) 2014-06-24 2023-03-16 샤이어 휴먼 지네틱 테라피즈 인크. Stereochemically enriched compositions for delivery of nucleic acids
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
US20170327524A1 (en) 2014-10-10 2017-11-16 Hoffmann-La Roche, Inc. Galnac phosphoramidites, nucleic acid conjugates thereof and their use
EP3020813A1 (en) 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
DK3234131T3 (en) 2014-12-16 2020-06-29 Roche Innovation Ct Copenhagen As Method of screening for chiral toxicity
ES2893114T3 (en) 2015-02-04 2022-02-08 Bristol Myers Squibb Co Methods for selecting therapeutic molecules
DK3253875T3 (en) 2015-02-04 2020-04-14 H Hoffmann La Roche Ag Tau antisense oligomers and uses thereof
KR20180073584A (en) 2015-10-02 2018-07-02 로슈 이노베이션 센터 코펜하겐 에이/에스 Oligonucleotide joining method
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
EP3430141B1 (en) 2016-03-14 2020-12-30 H. Hoffnabb-La Roche Ag Oligonucleotides for reduction of pd-l1 expression
EP3442983A1 (en) 2016-04-14 2019-02-20 H. Hoffnabb-La Roche Ag TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
MA45496A (en) 2016-06-17 2019-04-24 Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
US11479818B2 (en) 2016-06-17 2022-10-25 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
EP3472348B1 (en) 2016-06-17 2022-06-29 F. Hoffmann-La Roche AG In vitro nephrotoxicity screening assay
US10988763B2 (en) 2016-06-22 2021-04-27 Proqr Therapeutics Ii B.V. Single-stranded RNA-editing oligonucleotides
EP3478839A1 (en) 2016-07-01 2019-05-08 H. Hoffnabb-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
EP3494219A1 (en) 2016-08-03 2019-06-12 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
CN110352244B (en) 2016-09-01 2023-03-21 ProQR治疗上市公司Ⅱ Chemically modified RNA editing single stranded oligonucleotides
US20190367920A1 (en) 2017-01-13 2019-12-05 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb1 expression
US20190345496A1 (en) 2017-01-13 2019-11-14 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating relb expression
WO2018130581A1 (en) 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rela expression
US20190338286A1 (en) 2017-01-13 2019-11-07 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating rel expression
US20190345495A1 (en) 2017-01-13 2019-11-14 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018157154A2 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
WO2018177881A1 (en) 2017-03-29 2018-10-04 Roche Innovation Center Copenhagen A/S Unylinker rapid cleavage
CA3063531A1 (en) 2017-05-16 2018-11-22 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression
WO2019030313A2 (en) 2017-08-11 2019-02-14 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating ube3c expression
WO2019038228A1 (en) 2017-08-22 2019-02-28 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating tom1 expression
EP3694995A1 (en) 2017-10-13 2020-08-19 Roche Innovation Center Copenhagen A/S Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides
TW202424191A (en) 2017-10-16 2024-06-16 瑞士商赫孚孟拉羅股份公司 Nucleic acid molecule for reduction of papd5 and papd7 mrna for treating hepatitis b infection
PT3717646T (en) 2017-12-01 2025-07-28 Texas A & M Univ Sys Angelman syndrome antisense treatment
WO2019115416A2 (en) 2017-12-11 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating fndc3b expression
WO2019115417A2 (en) 2017-12-12 2019-06-20 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating rb1 expression
KR20200104339A (en) 2017-12-21 2020-09-03 에프. 호프만-라 로슈 아게 Companion diagnostic agent for HTRA1 RNA antagonists
CN111699258A (en) 2018-01-10 2020-09-22 哥本哈根罗氏创新中心 Oligonucleotides for modulating expression of PIAS4
PE20201501A1 (en) 2018-01-12 2020-12-29 Bristol Myers Squibb Co ANTI-SENSE OLIGONUCLEOTIDES ACTING ON ALPHA-SINUCLEIN, AND USES OF THESE
WO2019137974A1 (en) 2018-01-12 2019-07-18 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating gsk3b expression
KR102839166B1 (en) 2018-01-12 2025-07-28 브리스톨-마이어스 스큅 컴퍼니 Antisense oligonucleotides targeting alpha-synuclein and uses thereof
KR20200109338A (en) 2018-01-12 2020-09-22 로슈 이노베이션 센터 코펜하겐 에이/에스 Alpha-synuclein antisense oligonucleotides and uses thereof
CN111615558A (en) 2018-01-17 2020-09-01 罗氏创新中心哥本哈根有限公司 Oligonucleotides for Regulating ERC1 Expression
US20210095277A1 (en) 2018-01-18 2021-04-01 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting srebp1
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
RU2020125769A (en) 2018-02-09 2022-03-10 Дженентек, Инк. OLIGONUCLEOTIDES FOR MODULATION OF TMEM106B EXPRESSION
BR112020016347A2 (en) 2018-02-21 2021-01-12 Bristol-Myers Squibb Company CAMK2D ANTISENSE OLIGONUCLEOTIDS AND THEIR USES
EP3775208A1 (en) 2018-04-05 2021-02-17 F. Hoffmann-La Roche AG Use of fubp1 inhibitors for treating hepatitis b virus infection
AU2019252812A1 (en) 2018-04-13 2020-10-01 Bristol-Myers Squibb Company Novel phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds
US20210371860A1 (en) 2018-05-08 2021-12-02 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating myh7 expression
WO2019219723A1 (en) 2018-05-18 2019-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treatment of microrna related diseases
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
EP3802824A1 (en) 2018-06-05 2021-04-14 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
WO2020007702A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting bcl2l11
WO2020007700A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting spi1
WO2020007772A1 (en) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
CA3103054A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
WO2020007889A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting stat1
WO2020007826A1 (en) 2018-07-05 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mbtps1
WO2020011743A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting mafb
WO2020011653A1 (en) 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011744A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020011869A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting tlr2
WO2020011745A2 (en) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers6
JP7616987B2 (en) 2018-07-13 2025-01-17 エフ． ホフマン－ラ ロシュ アーゲー Oligonucleotides for modulating RTEL1 expression
WO2020038976A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting usp8
WO2020038971A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting vcan
WO2020038973A1 (en) 2018-08-23 2020-02-27 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting sptlc1
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
JP2021536239A (en) 2018-08-28 2021-12-27 ロシュ イノベーション センター コペンハーゲン エーエス Neoantigen manipulation with splice-regulating compounds
WO2020089260A1 (en) 2018-11-01 2020-05-07 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting tia1
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
JP2022514648A (en) 2018-12-21 2022-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Antisense oligonucleotides targeting CARD9
CN113507942A (en) 2019-03-05 2021-10-15 豪夫迈·罗氏有限公司 Intracellular targeting of molecules
JP7725370B2 (en) 2019-04-03 2025-08-19 ブリストル－マイヤーズ スクイブ カンパニー ANGPTL2 antisense oligonucleotides and uses thereof
EP3947677A1 (en) 2019-04-04 2022-02-09 F. Hoffmann-La Roche AG Oligonucleotides for modulating atxn2 expression
US11286485B2 (en) 2019-04-04 2022-03-29 Hoffmann-La Roche Inc. Oligonucleotides for modulating ATXN2 expression
WO2020245233A1 (en) 2019-06-06 2020-12-10 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting atxn3
JP2023506540A (en) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Use of SCAMP3 inhibitors to treat hepatitis B virus infection
JP2023506550A (en) 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Use of SBDS inhibitors to treat hepatitis B virus infection
WO2021122993A1 (en) 2019-12-19 2021-06-24 F. Hoffmann-La Roche Ag Use of saraf inhibitors for treating hepatitis b virus infection
JP7634542B2 (en) 2019-12-19 2025-02-21 エフ． ホフマン－ラ ロシュ アーゲー Use of SEPT9 inhibitors for treating hepatitis B virus infection - Patents.com
CN115516091A (en) 2019-12-19 2022-12-23 豪夫迈·罗氏有限公司 Use of COPS3 inhibitors for treating hepatitis B virus infection
JP7427227B2 (en) * 2020-01-21 2024-02-05 学校法人産業医科大学 KRAS antisense oligonucleotide that reduces tumor cell survival and its uses
WO2021158810A1 (en) 2020-02-05 2021-08-12 Bristol-Myers Squibb Company Oligonucleotides for splice modulation of camk2d
JP2023516142A (en) 2020-02-28 2023-04-18 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Oligonucleotides for modulating CD73 exon 7 splicing
JP2023527693A (en) 2020-05-11 2023-06-30 ジェネンテック， インコーポレイテッド Complement Component C1R Inhibitors and Related Compositions, Systems, and Methods of Using The Same for Treating Neurological Disorders
CN115551519A (en) 2020-05-11 2022-12-30 基因泰克公司 Complement Component C1S Inhibitors and Related Compositions, Systems, and Methods of Using Them for Treatment of Neurological Disorders
EP4150084A1 (en) 2020-05-11 2023-03-22 Genentech, Inc. Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
GB202006974D0 (en) 2020-05-12 2020-06-24 Univ Oxford Innovation Ltd Chimaeric proteins and therapeutic agents
AR122731A1 (en) 2020-06-26 2022-10-05 Hoffmann La Roche IMPROVED OLIGONUCLEOTIDES TO MODULATE FUBP1 EXPRESSION
JP2023538630A (en) 2020-08-21 2023-09-08 エフ． ホフマン－ラ ロシュ アーゲー Use of A1CF inhibitors to treat hepatitis B virus infection
US20220177883A1 (en) 2020-12-03 2022-06-09 Hoffmann-La Roche Inc. Antisense Oligonucleotides Targeting ATXN3
US20230060373A1 (en) 2020-12-03 2023-03-02 Hoffmann-La Roche Inc. Antisense Oligonucleotides Targeting ATXN3
CR20230308A (en) * 2020-12-11 2023-09-08 Civi Biopharma Inc ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETTING PCSK9
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
TW202246500A (en) 2021-02-02 2022-12-01 瑞士商赫孚孟拉羅股份公司 Enhanced oligonucleotides for inhibiting rtel1 expression
US20240294909A1 (en) 2021-02-12 2024-09-05 Merand Pharmaceuticals, Inc. Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
KR20230170691A (en) 2021-03-26 2023-12-19 뉴미르나 테라퓨틱스 에이피에스 MicroRNA-27b inhibitors
CA3213391A1 (en) 2021-03-26 2022-09-29 Markus Sakari Kauppinen Microrna-134 inhibitors
AU2022287241A1 (en) 2021-06-04 2023-12-14 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
EP4105328A1 (en) 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
US20250011793A1 (en) 2021-08-16 2025-01-09 Vib Vzw Oligonucleotides for Modulating Synaptogyrin-3 Expression
WO2023021184A1 (en) 2021-08-19 2023-02-23 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
EP4408999A1 (en) 2021-09-29 2024-08-07 F. Hoffmann-La Roche AG Rna editing
WO2023078883A1 (en) 2021-11-03 2023-05-11 F. Hoffmann-La Roche Ag Oligonucleotides for modulating apolipoprotein e4 expression
JP2024546993A (en) 2021-12-17 2024-12-26 エフ． ホフマン－ラ ロシュ アーゲー Oligonucleotide Combinations for Modulating RTEL1 and FUBP1
WO2023117738A1 (en) 2021-12-20 2023-06-29 F. Hoffmann-La Roche Ag Threose nucleic acid antisense oligonucleotides and methods thereof
CN118613268A (en) 2022-01-20 2024-09-06 基因泰克公司 Antisense oligonucleotides for regulating TMEM106B expression
AU2023258547A1 (en) 2022-04-29 2024-12-05 Haya Therapeutics Sa Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis
CN119173632A (en) 2022-05-10 2024-12-20 豪夫迈·罗氏有限公司 Antisense oligonucleotides targeting the CFP-ELK1 intergenic region
EP4332221A1 (en) 2022-08-29 2024-03-06 Roche Innovation Center Copenhagen A/S Threose nucleic acid antisense oligonucleotides and methods thereof
WO2024098061A2 (en) 2022-11-04 2024-05-10 Genkardia Inc. Oligonucleotide-based therapeutics targeting cyclin d2 for the treatment of heart failure
EP4619524A1 (en) 2022-11-18 2025-09-24 Genkardia Inc. Methods and compositions for preventing, treating, or reversing cardiac diastolic dysfunction
WO2024160756A1 (en) 2023-01-30 2024-08-08 Vib Vzw Suppressors of tauopathies
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2024227765A2 (en) 2023-05-04 2024-11-07 F. Hoffmann-La Roche Ag Oligonucleotides capable of upregulating glucocerebrosidase expression
WO2024241091A2 (en) 2023-05-22 2024-11-28 Haya Therapeutics Sa Compositions and methods to modulate transposable elements governing cell-state transitions
WO2024261531A2 (en) 2023-06-23 2024-12-26 Haya Therapeutics Sa Compositions and methods to modulate tumor microenvironment associated long noncoding rnas
EP4512899A1 (en) 2023-08-23 2025-02-26 Lipigon Pharmaceuticals AB Angptl4 aso compositions for treatment of atherosclerosis in humans
CN117563009B (en) 2023-09-01 2025-07-01 杭州天龙药业有限公司 GalNAc compound containing ribose ring or derivative structure thereof and oligonucleotide conjugate thereof
WO2025088373A1 (en) 2023-10-25 2025-05-01 Haya Therapeutics Sa Compositions and methods of modulating long noncoding transcripts associated with ards induced pulmonary fibrosis
WO2025125542A1 (en) 2023-12-15 2025-06-19 F. Hoffmann-La Roche Ag Intrathecal dosage method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013670A1 (en) * 1992-10-05 2003-01-16 Monia Brett P. Antisense oligonucleotide inhibition of ras

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013670A1 (en) * 1992-10-05 2003-01-16 Monia Brett P. Antisense oligonucleotide inhibition of ras

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM C C ET AL: "A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma", CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 92, no. 5, 1 September 2001 (2001-09-01), pages 1265 - 1271, XP002232130, ISSN: 0008-543X *
FLUITER K ET AL: "ON THE IN VITRO AND IN VIVO PROPERTIES OF FOUR LOCKED NUCLEIC ACID NUCLEOTIDES INCORPORATED INTO AN ANTI-H-RAS ANTISENSE OLIGONUCLEOTIDE", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 6, no. 6, 6 June 2005 (2005-06-06), pages 1104 - 1109, XP009069506, ISSN: 1439-4227 *
GILES R V ET AL: "ENHANCED RNASE H ACTIVITY WITH METHYLPHOSPHONODIESTER/ PHOSPHODIESTER CHIMERIC ANTISENSE OLIGODEOXYNUCLEOTIDES", ANTI-CANCER DRUG DESIGN, BASINGSTOKE, GB, vol. 7, no. 1, 1 February 1992 (1992-02-01), pages 37 - 48, XP000618243, ISSN: 0266-9536 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852627B2 (en) 2015-11-12 2023-12-26 Hoffmann-La Roche Inc. Oligonucleotides for inducing paternal UBE3A expression

Also Published As

Publication number Publication date
WO2007031091A2 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
WO2007031091A3 (en) Rna antagonist compounds for the modulation of p21 ras expression
WO2007031081A3 (en) RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
WO2004069992A3 (en) Oligomeric compounds for the modulation of ras expression
WO2004069991A3 (en) Oligomeric compounds for the modulation of survivin expression
WO2007101227A8 (en) Identification and use of novopeptides for the treatment of cancer
WO2008154249A3 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2011008429A (en) Methods and compositions for diagnosis and treatment of cancer.
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2007074193A3 (en) Method for the analysis of differential expression in colorectal cancer
WO2005113816A3 (en) Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2008097466A3 (en) Metastasis specific splice variants of mena and uses thereof in diagnosis, prognosis and treatment of tumors
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
WO2010022166A3 (en) Micro rna and neurofibromatosis type 1 in diagnosis and therapy
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
WO2006061216A3 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
WO2007092944A8 (en) Compositions and methods involving gene therapy and proteasome modulation
WO2007002746A3 (en) Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
Hollande et al. The long road to colorectal cancer therapy: searching for the right signals
WO2009071680A3 (en) Rna antagonist compounds for the modulation of mcl-1
WO2011051271A3 (en) Prostate tumor markers and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06775997

Country of ref document: EP

Kind code of ref document: A2